Next Generation Sequencing in MPNs. Lessons from the Past and Prospects for Use as Predictors of Prognosis and Treatment Responses.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed, 37 citations in OpenAlex.

1. Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.Blood advances · 2022
   Trial
2. A paradigm shift in the treatment of patients with polycythemia vera. The initial early use of recombinant interferon-alpha.Leukemia · 2026
   Review
3. CALR-mutant myeloproliferative neoplasms: insights from next-generation sequencing.Journal of applied genetics · 2026
   Article
4. Advances in the Diagnosis and Treatment of Myeloproliferative Neoplasms (MPNs).Cancers · 2025
   Review
5. Molecular landscape of non-driver genes in myeloproliferative neoplasms through 333 cancer genes panel: Insights to reveal in Pakistan.BMC medical genomics · 2025
   Article
6. Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis.Life (Basel, Switzerland) · 2024
   Article
7. Molecular landscape of theBiomedical reports · 2023
   Article
8. A novel germline hyperactivating JAK2 mutation L604F.Annals of hematology · 2023
   Article
9. Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.Cancers · 2023
   Review
10. Myelofibrosis and Survival Prognostic Models: A Journey between Past and Future.Journal of clinical medicine · 2023
    Review
11. A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2.Cancer medicine · 2023
    Article
12. Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023
    Review
13. Case Report: First longitudinal study of a patient with CALR positive clonal hematopoiesis of indeterminate potential developing into pre-fibrotic myelofibrosis.Frontiers in oncology · 2023
    Article
14. Acute Myeloid Leukemia Following Myeloproliferative Neoplasms: A Review of What We Know, What We Do Not Know, and Emerging Treatment Strategies.Journal of hematology · 2022
    Review
15. Recombinant Interferon-β in the Treatment of Polycythemia Vera and Related Neoplasms: Rationales and Perspectives.Cancers · 2022
    Article
16. The Contribution ofInternational journal of molecular sciences · 2022
    Review
17. Clinical Features, Gene Alterations, and Outcomes in Prefibrotic and Overt Primary and Secondary Myelofibrotic Patients.Cancers · 2022
    Article
18. Genetic Background of Polycythemia Vera.Genes · 2022
    Review
19. Biomolecules · 2022
    Review
20. The Classification of Myeloproliferative Neoplasms: Rationale, Historical Background and Future Perspectives with Focus on Unclassifiable Cases.Cancers · 2021
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as